Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis
- Conditions
- Liver Steatosis
- Interventions
- Device: FibroscanBiological: Blood test for biological assessment of liver functionDevice: MRI
- Registration Number
- NCT02575625
- Lead Sponsor
- University Hospital, Tours
- Brief Summary
Hypothesis of this study is the existence of a relation between parameters measured by FibroScan® FS 502 according to our non invasive method and liver steatosis condition.
This proof of concept validation is made up of two steps:
* Step 1: feasibility study of the method on 10 healthy volunteers
* Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an liver biopsy et whom the histological answer is clean steatosis (NAFLD).
Experimental procedures consist in:
* Fibroscan measure, preceded by tracking ultrasonography.
* liver MRI (for substudy about MRI comparison, in step 2)
* a blood test for biological assessment of liver functions
- Detailed Description
Diagnosis of liver lipid overload (named liver steatosis), unrelated to alcohol consumption, still mainly based on histological exam of the liver. An histological continuity exists going from clean liver steatosis (Non Alcoholic Fatty Liver Disease, NAFLD) to steatohepatitis with signs of inflammation and tissue fibrosis (Non Alcoholic Steato-Hepatitis, NASH). It's now well-known that disease can evolve to cirrhosis and its complications.
Hypothesis of this study is the existence of a relation between parameters measured by FibroScan® FS 502 according to our non invasive method and liver steatosis condition.
This proof of concept validation is made up of two steps:
* Step 1: feasibility study of the method on 10 healthy volunteers
* Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an liver biopsy et whom the histological answer is clean steatosis (NAFLD).
Measures on healthy volunteers enable to do an intra-operator reproductibility analysis, a study of an age effect and a search of potential mechanic aging of the liver.
Experimental procedures consist in:
* Fibroscan measure, preceded by tracking ultrasonography.
* liver MRI (for substudy about MRI comparison, in step 2)
* a blood test for biological assessment of liver functions
The final aim of this study is to propose a device enable medical community to do in vivo hepatic rheology observation, highly correlated to liver lipid overload. After industrialization of this innovation, this diffusion could making easier patients follow-up.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 85
-
Healthy subjects - Steps 1 and 2
- Age between 18 and 65 years old (2 age groups for step 2 : 18-30 et 40-65 years-old)
- Written inform consent form signed
- Affiliated to medical insurance
- Alcohol consumption d'alcool < 20g/j for women, <30g/j for men
-
Patients with liver steatosis - Step 2
- More than 18 years -old
- Written inform consent form signed
- Affiliated to medical insurance
- Patients with clean steatosis confirmed by histological results of a liver biopsy done the previous month
- Alcohol consumption d'alcool < 20g/j for women, <30g/j for men
-
Healthy subjects - Step 1
- Exposure to chemical poisons (solvents, paints, drugs) in the previous 4 weeks
- Pregnant women, lactating women, and women in age for procreation and without reliable contraception
- Presence of ascites
- Person under guardianship
-
Healthy subjects - Step 2
- Exposure to chemical poisons (solvents, paints, drugs) in the previous 4 weeks
- Pregnant women, lactating women, and women in age for procreation and without reliable contraception
- Contraindication to MRI
- Presence of ascites
- Person under guardianship
-
Healthy subjects - Steps 1 and 2
- Presence of liver tumor or ascites (diagnosed with MRI or ultrasonography)
- Abnormal liver function tests (increase of transaminases, gammaGT)
-
Patients with liver steatosis - Step 2
- Exposure to chemical poisons (solvents, paints, drugs) in the previous 4 weeks
- Pregnant women, lactating women, and women in age for procreation and without reliable contraception
- Contraindication to MRI
- Presence of ascites
- liver tumor
- Serology anti VHC+ or Ag HBs+
- Infection by HIV
- Auto-immun hepatitis
- Genetic hemochromatosis, Wilson disease, lake of alpha-1-antitrypsin
- Fibrosis or liver cirrhosis at biopsy
- Person under guardianship
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Fibroscan exam Blood test for biological assessment of liver function Step 1: feasibility study of the method on 10 healthy volunteers Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an hepatic biopsy et whom the histological answer is clean steatosis (NAFLD). Experimental procedures consist in: * Fibroscan measure, preceded by tracking sonography. * liver MRI (for substudy about MRI comparison, in step 2) * a blood test for biological assessment of liver functions Fibroscan exam MRI Step 1: feasibility study of the method on 10 healthy volunteers Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an hepatic biopsy et whom the histological answer is clean steatosis (NAFLD). Experimental procedures consist in: * Fibroscan measure, preceded by tracking sonography. * liver MRI (for substudy about MRI comparison, in step 2) * a blood test for biological assessment of liver functions Fibroscan exam Fibroscan Step 1: feasibility study of the method on 10 healthy volunteers Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an hepatic biopsy et whom the histological answer is clean steatosis (NAFLD). Experimental procedures consist in: * Fibroscan measure, preceded by tracking sonography. * liver MRI (for substudy about MRI comparison, in step 2) * a blood test for biological assessment of liver functions
- Primary Outcome Measures
Name Time Method Viscosity in Pa.s One day Digital files recorded by medical device will be mathematically processed for extracting elasticity G' and viscosity G'' curves in accordance with the frequency. These curves use to identify the 5 parameters: mu(M), eta(M), alpha, mu(V), eta(V); which describe visco-elasticity variations with frequency thanks to an Matlab algorithm
Elasticity in kPa One day Digital files recorded by medical device will be mathematically processed for extracting elasticity G' and viscosity G'' curves in accordance with the frequency. These curves use to identify the 5 parameters: mu(M), eta(M), alpha, mu(V), eta(V); which describe visco-elasticity variations with frequency thanks to an Matlab algorithm
- Secondary Outcome Measures
Name Time Method Reproductibility quantification in arbitrary unit through study completion, an average of 2 years The 5 estimated parameters (which describe visco-elasticity) will be used to quantify the medical device reproductibility
Age in years through study completion, an average of 2 years The 5 estimated parameters (which describe visco-elasticity) and the age oh the healthy volunteers wil be used to study an age effect
Liver signal intensity changes in decibel through study completion, an average of 2 years Adiposis charge will be assessed by measure of liver signal intensity decrease on T1 sequence in phase opposition compared to in phase signal, after correction by iron quantity
Trial Locations
- Locations (1)
University Hospital of Tours
🇫🇷Tours, France